论文部分内容阅读
血管紧张素转换酶抑制剂(ACEI)在心血管领域应用广泛,不论是治疗高血压、心力衰竭,还是心肌梗死,都有大量的循证医学证据。但其临床应用情况与指南的要求有很大差距,如该用药者未用药, 已经用药者未能剂量达标。为了提高中国临床医生的心血管诊治水平和规范用药,在百时美施贵宝公司的支持下,中华医学会心血管病学分会计划在“ESC(欧洲心脏病学会)-ACEI专家共识”的基础上,制定“中国ACEI专家共识”,以更好指导和规范临床医生对ACEI的正确认识和临床使用。作为制订“中国ACEI专家共识”活动的重要一步,4月14日,“中欧心血管论坛暨中国ACEI专家共识制定第二次专家会”在北京召开。大会由中华医学会心血管病学分会主任委员高润霖教授主持,邀请ESC-ACEI专家共识工作组主席JL Sendon教授等专家出席,介绍了ESC—ACEI专家共识的制定情况和内容,并探讨了“中国ACEI专家共识”制定的相关问题。以下为此次会议中的部分发言内容。
Angiotensin converting enzyme inhibitors (ACEIs) are widely used in the field of cardiovascular medicine, and there is a great deal of evidence-based medicine for treating hypertension, heart failure and myocardial infarction. However, the clinical application of the guidelines and requirements there is a big gap, such as the drug was not medication, have been medication failed to dose compliance. With the support of Bristol-Myers Squibb in order to improve the cardiovascular diagnosis and treatment of Chinese clinicians and to standardize their medication, the Chinese Medical Association’s Cardiology Branch plans to establish the “ESC (European Society of Cardiology) -ACEI Expert Consensus” , The development of “China ACEI expert consensus” to better guide and regulate clinicians correct understanding of ACEI and clinical use. As an important step in formulating the “ACEI Expert Consensus of China”, on April 14, “China-EU Cardiovascular Forum and the Second Expert Meeting of China ACEI Expert Consensus” were held in Beijing. The conference was chaired by Professor Gao Runlin, chairman of the Cardiology Branch of the Chinese Medical Association and invited experts such as Prof. JL Sendon, chairman of ESC-ACEI Expert Consensus Working Group to attend the conference to introduce the formulation and content of the ESC-ACEI expert consensus and to discuss “China ACEI expert consensus ”to develop the relevant issues. The following is part of the speech in this meeting.